



*How to maintain a robust
and objective scientific
dialogue between
government and
stakeholder experts?*

An NGO Perspective

Angeliki Lyssimachou, PhD – Environmental Toxicologist

Workshop: *“What does the future hold for harmonised human health risk assessment of plant protection products?”*

Berlin, BfR premises, 20th November 2017

EU Law



Lisbon Treaty (2009)


- Open decision making
- Citizens participation
- Transparency
- Good administration




Survey – Questionnaire



- 10 Questions
- 17 NGO replies




Survey – Question 1




“Do you agree that governments should consult with stakeholders (industry and NGOs) during the risk assessment procedure of plant protection products (PPPs)?”

Survey – Question 2




“In your opinion, do you consider that there is currently a scientific dialogue between governments and NGOs during the risk assessment procedure of PPPs?”

Survey – Question 3



“Do you consider that your NGO is engaged in a dialogue with government during the procedure of pesticide risk assessment?”


Survey – Question 4



“In your perspective is the current dialogue with government and stakeholders (industry and NGOs) transparent?”*

*Transparency: The general public can find out how many exchanges have taken place and when, the content and how the governments have responded.


Survey – Question 5



“In your opinion, in which phase should stakeholders (industry and NGOs) participate in the risk assessment of PPPs?”


- *A: During DAR/RAR*
- *B: During EFSA peer-review*
- *C: During both phases*

Survey – Question 6




“In your perspective, should stakeholders (NGOs and industry) participate as observers in SCoPAFF, where the pesticide dossiers are discussed with Member States and decisions are taken?”

Survey – Question 7



*“In your experience, do you feel that governments take into account **your opinion (NGO)**, during the pesticide risk assessment procedure?”*

Survey – Question 8




*“In your experience, do you feel that governments take into account the opinion of **industry stakeholders**, during the pesticide risk assessment procedure?”*

Survey – Question 9




“In your perspective what are the main limitations (or flaws) for a robust and objective dialogue between government and NGOs during the process of pesticide risk assessment?”



Survey – Question 10



“What do you think are the main limitations (or flaws) currently in the pesticide risk assessment?”




An example - Glyphosate



■ Carcinogenicity

- OECD TGs, adult animals, high dose range (810 – 4841 mg/kg)
- Tumours in 5 mice studies – after revision significant





Survey Highlights - proposals

- Increase transparency throughout the process and reduce complexity
 - Clear reporting & scientific justification with proof, publish industry-sponsored studies, use independent scientific literature, eliminate data gaps, use systematic review, apply the precautionary principle
- Involve experts from the civil society and academia:
 - Workshops, trainings, regular meetings, briefings
 - Consider the limited resources
- Reduce the involvement of industry in the assessment of its own products
 - RA should be based on the work of independent experts



Is RA missing the forest for the trees?

■ EU Regulation 1107/2009

*“The purpose of this Regulation is to ensure **a high level of protection of both human and animal health and the environment** and at the same time to safeguard the competitiveness of Community agriculture. Particular attention should be paid to the protection of vulnerable groups of the population, including pregnant women, infants and children. The **precautionary principle** should be applied and this Regulation should ensure that industry demonstrates that substances or products produced or placed on the market **do not have any harmful effect** on human or animal health or any unacceptable effects on the environment.”*

Relevance

Reliability



- Reliability
 - “Free from bias”
 - “Risk of bias” at all levels including financial bias
 - Design (housing, controls), performance, analysis, modifications, reporting, statistics
 - GLP does not guarantee scientific quality



Future of Risk Assessment

- Systematic review
- Integration of all lines of evidence (Weight of Evidence):
 - In silico, in vivo, in vitro, epidemiology
 - Studies on products, other adverse effects than data requirements (obesity, diabetes, brain function), data gaps
 - Include several independent reviewers
 - Highlight uncertainties for further research and regulatory actions

Integration of data – WoE example



Industry-sponsored
studies
(OECD TG protocol)



Non-sensitive for low doses
and latent effects, limited
endpoints,
high risk of bias due to conflict
of interest

Peer-reviewed literature
studies
(non OECD TG protocols)



Low-dose exposures, non-
monotonic, real-life exposures,
additional endpoints, effects of
mixtures, latent effects,
mechanistic data



Thank you!

